Introduction {#s1}
============

CD4 cell count is a major indicator of human immunodeficiency virus (HIV) infection disease progression [@pone.0096098-Mellors1], [@pone.0096098-Hogg1]. Patients who receive a late diagnosis, defined as a baseline CD4 cell count\<200 cells/µl, have significantly poorer responses to antiretroviral therapy (ART) and worse prognoses [@pone.0096098-Dybul1], [@pone.0096098-Hammer1], [@pone.0096098-Chaisson1], [@pone.0096098-Chadborn1]. The proportion of patients who present late to diagnosis and treatment remains unacceptably high [@pone.0096098-Buchacz1], [@pone.0096098-Ogbuanu1], [@pone.0096098-Gardner1], [@pone.0096098-Althoff1]. Internationally, the observed proportion of patients with late diagnoses is stable or worsening [@pone.0096098-Buchacz1]. Although it is recommended that CD4 cell count testing should be carried out promptly after diagnosis, many patients fail to receive on-time testing [@pone.0096098-Easterbrook1], [@pone.0096098-CD41]. In the United States, an ongoing outpatient study in eight cities found that 78% of patients had a measured CD4 count within 3 months of HIV diagnosis [@pone.0096098-Buchacz1]. This proportion was significantly lower in developing countries. Studies in Thailand, Vietnam, and South Africa reported that only 34%, 49%, and 62.6% of patients, respectively, received CD4 count assessment with 6 months of HIV diagnosis [@pone.0096098-Thanawuth1], [@pone.0096098-Tran1], [@pone.0096098-Kranzer1].

In 2002, China implemented the National Free Antiretroviral Therapy Program (NFATP) to address the issue of poor access to HIV/AIDS treatment. Patients who meet the national treatment criteria of a CD4 count ≤200 cells/µl (revised to ≤350cells/µl in 2008) are eligible for ART at no cost to the patient [@pone.0096098-Zhang1]. The program has contributed to a dramatic reduction in mortality among patients receiving HIV treatment [@pone.0096098-Zhang2]. In order to expand NFATP coverage, the government has increased HIV screening access, leading to a rise in the number of people diagnosed with HIV [@pone.0096098-Wu1]. After the diagnosis of HIV infection, timely CD4 cell count testing is a crucial step in determining whether the patient meets criteria for ART initiation and engaging the patient in appropriate care and treatment [@pone.0096098-Zhang3], [@pone.0096098-Zhang4]. From 2007, the national HIV/AIDS program set quantitative targets of core indicators to monitor progress in key areas of HIV work. From 2007 to 2009, the proportion of CD4 cell count monitoring for people diagnosed with HIV and AIDS increased from 45.3% and 10.1% in 2007 to 54.2% and 62.5% in 2009, respectively [@pone.0096098-Liu1].

However, past studies have indicated that many patients are lost or delayed along the continuum of care. A study in Guangxi and Yunnan found that only 37% of patients who were diagnosed with HIV from 2005 to 2009 received baseline CD4 testing within 6 months [@pone.0096098-Zhang4]. The proportion increased dramatically from 7% in 2005 to 62% in 2009. A separate study noted that in 2009, approximately 30% of the ART-initiated patients who received baseline CD4 testing had CD4 \<50 cells/µl, indicating that many patients were being diagnosed and treated late [@pone.0096098-Wen1], [@pone.0096098-Dou1]. Prompt baseline CD4 testing is a critical step in successful linkage to HIV treatment.

By using data extracted from the Chinese HIV/AIDS Comprehensive Response Information Management System (CRIMS) [@pone.0096098-Mao1], we aimed to identify trends in the proportion of individuals who received timely baseline CD4 cell count testing within 6 months of HIV diagnosis in China from 2006 to 2012. We also sought to determine changes in median baseline CD4 cell counts over time and factors associated with failing to receive CD4 cell count testing.

Methods {#s2}
=======

Data source {#s2a}
-----------

Data were collected from CRIMS, a web-based real-time database system managed by the National Centre for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (CDC). CRIMS was developed in 2005 and has previously been described elsewhere [@pone.0096098-Mao1]. Local CDC staffs, who are trained on data upload and management, create electronic records in CRIMS for each patient who tests positive for HIV. Staffs receive annual refresher training. Patient records contain information on demographic characteristics, contact information (including both permanent and temporary residential addresses), sexual and drug use risk behaviors, likely transmission routes, medical histories, and laboratory test results [@pone.0096098-Mao1]. For this study, we included all adult individuals (over 15 years old) who received a confirmed HIV diagnosis between January 1, 2006 and December 31, 2012. All HIV screening is done in accordance with national HIV policy. Provider-initiated testing and counseling (PITC) has been in place in hospitals since 2007.

Data analysis {#s2b}
-------------

The primary outcome of interest was the proportion of newly diagnosed HIV/AIDS individuals who received baseline CD4 cell count testing within 6 months of diagnosis. Data were described by the median (interquartile range, IQR) and the distribution across four CD4 cell count categories (\<200, 200--349, 350--500, and ≥500). Demographic characteristics were analyzed using chi-squared statistics for dichotomous and categorical variables. Univariate and multivariate logistic regression models were used to assess the factors associated with not receiving a timely CD4 cell count. Variables with p\<0.10 under univariate analysis were retained for multivariate modeling using stepwise selection, and 95% confidences intervals were estimated using these models. Results with a two-sided p\<0.01 were considered statistically significant. All data analyses were performed using SAS Version 9.3 (SAS Institute, Cary, NC, USA).

Ethics statement {#s2c}
----------------

This study was a secondary data analysis using existing Chinese government HIV/AIDS CRIMS data. All subjects signed a general informed consent upon enrollment to CRIMS indicating that their data, after removing personal identifiers, could be used in statistical analyses and/or epidemiological research studies. Therefore, no additional study specific informed consent was necessary for this current study. Patient records and information were de-identified prior to analysis. This study protocol was reviewed and approved by the Institutional Review Board of the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention (approval \#X130205248).

Results {#s3}
=======

Between January 1, 2006 and December 31, 2012, there were 394,294 individuals newly diagnosed with HIV infection in China. Patients under 15 years of age (N = 5,798) were excluded from the study cohort. Of the remaining 388,496 newly diagnosed individuals, 221,980 (57.1%) patients received a baseline CD4 cell count within 6 months of HIV diagnosis over the six-year study period ([Table 1](#pone-0096098-t001){ref-type="table"}).

10.1371/journal.pone.0096098.t001

###### Baseline CD4 cell counts (within 6 months of diagnosis) of HIV individuals in China: 2006--2012.

![](pone.0096098.t001){#pone-0096098-t001-1}

                                                                            2006           2007           2008            2009            2010            2011            2012            Total
  -------------------------------------------------------------------- -------------- -------------- --------------- --------------- --------------- --------------- --------------- ---------------
  No. (%) of subjects with baseline CD4 cells counts within one year                                                                                                                 
  \<15 days                                                             3812 (10.9)    7021 (17.3)    12038 (25.3)    16332 (29.9)    20544 (35.4)    29437 (41.1)    37561 (46.1)    126745 (32.6)
  \<30 days                                                             4608 (13.1)    8472 (20.9)    14538 (30.5)    20172 (37.0)    25372 (43.7)    36712 (51.6)    46753 (57.4)    156627 (40.3)
  \<90 days                                                             5893 (16.8)    10949 (27.0)   18340 (38.5)    25434 (46.6)    32467 (55.9)    46623 (65.5)    57773 (71.0)    197479 (50.8)
  \<180 days                                                            7030 (20.0)    13125 (32.4)   21122 (44.3)    29078 (53.3)    37081 (63.8)    51957 (73.0)    62587 (76.9)    221980 (57.1)
  Median (IQR) baseline CD4 cell count                                  221(63--410)   252(80--429)   280(106--448)   287(116--454)   295(130--459)   299(140--454)   314(159--460)   294(130--454)
  No. (%) of subjects with CD4 cell counts (cells/µl)                                                                                                                                
  \<200                                                                 3298 (46.9)    5552 (42.3)     7851 (37.2)    10620 (36.5)    12751 (34.4)    17266 (33.2)    19244 (30.7)    76582 (34.5)
  200--349                                                              1476 (21.0)    2941 (22.4)     5062 (24.0)     6858 (23.6)     9062 (24.4)    12877 (24.8)    15584 (24.9)    53860 (24.3)
  350--499                                                              1066 (15.2)    2299 (17.5)     4092 (19.4)     5802 (20.0)     7800 (21.0)    11691 (22.5)    15241 (24.4)    47991 (21.6)
  ≥500                                                                  1190 (16.9)    2333 (17.8)     4117 (19.5)     5798 (19.9)     7468 (20.1)    10123 (19.5)    12518 (20.0)    43547 (19.6)

The number of newly identified HIV cases with measured baseline CD4 counts more than doubled between 2006 and 2012, increasing from 35,087 to 81,416. The proportion of newly diagnosed individuals who received a baseline CD4 cell count test within 6 months increased from 20.0% in 2006 to 76.9% in 2012. National policies recommend CD4 cell count testing within 14 days after diagnosis of HIV infection. Our study found that the proportion of newly diagnosed individuals who received baseline CD4 cell count testing within 14 days increased from 10.9% in 2006 to 46.1% in 2012 ([Table 1](#pone-0096098-t001){ref-type="table"}).

The median baseline CD4 cell count of individuals who received timely testing over the study period was 294 cells/µl (IQR: 130--454). Over half of the patients (N = 130,442, 58.8%) had baseline CD4 cell counts \<350 cells/µl, and 76,582 patients (34.5%) had baseline CD4 cell counts \<200 cells/µl. Less than a quarter of patients (N = 43,547, 19.6%) had baseline CD4 cell counts ≥500 cells/µl ([Table 1](#pone-0096098-t001){ref-type="table"}).

The median baseline CD4 cell count increased slightly by each calendar year over the study period from 221 cells/µl (IQR: 63--410) in 2006 to 314 cells/µl (IQR: 159--460) in 2012. The percentage of individuals with baseline CD4 cell counts \<200 cells/µl, indicating advanced disease, decreased from 46.9% in 2006 to 30.7% in 2012. The percentage of individuals diagnosed with baseline CD4 cell counts ≥500 cells/µl, indicating a recent acquisition of HIV infection, has remained relatively stable ([Table 1](#pone-0096098-t001){ref-type="table"}).

Characteristics associated with receiving baseline CD4 cell count testing within 6 months were being female, being married, having attained middle school education or higher, having acquired HIV through male-to-male sexual contact or commercial blood plasma donation, and being diagnosed with HIV infection at a voluntary counseling and testing (VCT) clinic ([Table 2](#pone-0096098-t002){ref-type="table"}). A total of 34,248 newly diagnosed individuals (8.8%) died within 6 months after HIV diagnosis. Of these individuals, 23,661 (69.1%) had not received CD4 cell count testing.

10.1371/journal.pone.0096098.t002

###### Factors associated with baseline CD4 cell counts (within 6 months of diagnosis) of HIV individuals in China: 2006--2012, based on multivariate logistic regression analysis.

![](pone.0096098.t002){#pone-0096098-t002-2}

                                                         No. of new cases   No. (%) of subjects with baseline CD4 cell count   Unadjusted OR (95% CI)   P-value   Adjusted OR (95% CI)   P-value
  ----------------------------------------------------- ------------------ -------------------------------------------------- ------------------------ --------- ---------------------- ---------
  Year of HIV diagnosis                                                                                                                                                                 
  2006                                                        35087                           7030 (20.0)                               1.00                              1.00          
  2007                                                        40491                           13125 (32.4)                       0.52 (0.51--0.54)      \<0.01     0.57 (0.55--0.59)     \<0.01
  2008                                                        47675                           21122 (44.3)                       0.32 (0.31--0.33)      \<0.01     0.39 (0.38--0.40)     \<0.01
  2009                                                        54552                           29078 (53.3)                       0.22 (0.21--0.23)      \<0.01     0.28 (0.27--0.29)     \<0.01
  2010                                                        58109                           37081 (63.8)                       0.14 (0.14--0.15)      \<0.01     0.19 (0.18--0.20)     \<0.01
  2011                                                        71166                           51957 (73.0)                       0.09 (0.09--0.10)      \<0.01     0.13 (0.12--0.13)     \<0.01
  2012                                                        81416                           62587 (76.9)                       0.08 (0.07--0.08)      \<0.01     0.11 (0.10--0.11)     \<0.01
  Gender                                                                                                                                                                                
  Female                                                      113340                          67460 (59.5)                              1.00                              1.00          
  Male                                                        275156                         154520 (56.2)                       1.15 (1.13--1.16)      \<0.01     1.17 (1.15--1.19)     \<0.01
  Age (years)                                                                                                                                                                           
  15--24                                                      58323                           31195 (53.5)                              1.00                              1.00          
  25--34                                                      132737                          70982 (53.5)                       1.00 (0.98--1.02)       0.96      0.82 (0.80--0.84)     \<0.01
  35--44                                                      101295                          58885 (58.1)                       0.83 (0.81--0.85)      \<0.01     0.80 (0.78--0.82)     \<0.01
  45--54                                                      43726                           28773 (65.8)                       0.60 (0.58--0.61)      \<0.01     0.80 (0.78--0.83)     \<0.01
  55+                                                         52415                           32145 (61.3)                       0.73 (0.71--0.74)      \<0.01     1.03 (1.00--1.06)      0.03
  Marital status                                                                                                                                                                        
  Single, divorced, or widowed                                175776                         101301 (57.6)                              1.00                              1.00          
  Married or lives with partner                               201596                         119162 (59.1)                       0.94 (0.93--0.95)      \<0.01     0.87 (0.86--0.89)     \<0.01
  Education                                                                                                                                                                             
  Middle school or above                                      231092                         145738 (63.1)                              1.00                              1.00          
  Primary school or below                                     145077                          75502 (52.0)                       1.57 (1.55--1.60)      \<0.01     1.30 (1.28--1.32)     \<0.01
  Occupation                                                                                                                                                                            
  Other[\*](#nt101){ref-type="table-fn"}                      210105                         119033 (56.7)                              1.00            \<0.01            1.00          
  Farmer or rural laborer                                     178391                         102947 (57.7)                       0.96 (0.95--0.97)                 0.99 (0.97--1.00)      0.15
  Ethnicity                                                                                                                                                                             
  Minority group                                              117896                          53500 (45.4)                              1.00                              1.00          
  Han                                                         270600                         168480 (62.3)                       0.50 (0.50--0.51)      \<0.01     0.76 (0.74--0.77)     \<0.01
  Route of HIV infection                                                                                                                                                                
  Heterosexual contact                                        222148                         143431 (64.6)                              1.00                              1.00          
  Male-to-male sexual contact                                 44840                           35277 (78.7)                       0.49 (0.48--0.51)      \<0.01     0.62 (0.60--0.64)     \<0.01
  Injection drug use                                          76815                           26791 (34.9)                       3.40 (3.34--3.46)      \<0.01     2.07 (2.02--2.12)     \<0.01
  Sexual contact and injection drug use                        5030                           2111 (42.0)                        2.52 (2.38--2.67)      \<0.01     1.87 (1.76--1.99)     \<0.01
  Blood (plasma) donation                                     17204                           10429 (60.6)                       1.18 (1.15--1.22)      \<0.01     0.83 (0.81--0.87)     \<0.01
  Site of HIV diagnosis                                                                                                                                                                 
  VCT centers                                                 110360                          73316 (66.4)                              1.00                              1.00          
  Hospitals                                                   153367                          87886 (57.3)                       1.48 (1.45--1.50)      \<0.01     1.91 (1.88--1.95)     \<0.01
  Detention centers                                           47218                           14846 (31.4)                       4.32 (4.22--4.42)      \<0.01     1.75 (1.70--1.80)     \<0.01
  Others[\*\*](#nt102){ref-type="table-fn"}                   77551                           45932 (59.2)                       1.36 (1.34--1.39)      \<0.01     1.42 (1.39--1.46)     \<0.01
  Migrant worker[\*\*\*](#nt103){ref-type="table-fn"}                                                                                                                                   
  No                                                          294016                         177081 (60.2)                              1.00                              1.00          
  Yes                                                         94480                           44899 (47.5)                       1.67 (1.65--1.70)      \<0.01     1.55 (1.53--1.58)     \<0.01
  Total                                                       388496                         221980 (57.1)                               \-               \-               \-              \-

\*Includes laborer, unemployed, businessman, student, public servant, and unclear.

\*\*Includes targeted intervention project, physical examination for sex workers, and unclear.

\*\*\*Defined as having migrated from the registered region of residence to another region for at least six months.

In the univariate logistic regression model, factors associated with baseline CD4 cell count testing within 6 months of HIV diagnosis were age group, gender, marital status, education level, ethnicity, employment as a migrant worker, route of HIV transmission, site of HIV diagnosis, and year of HIV diagnosis ([Table 2](#pone-0096098-t002){ref-type="table"}).

In the multivariate logistic regression model ([Table 2](#pone-0096098-t002){ref-type="table"}), predictors for not receiving CD4 cell count testing with 6 months included being male (OR: 1.17, 95% CI: 1.15--1.19), age 55 years or older (OR: 1.03, 95% CI: 1.00--1.06), educational attainment of primary school or below (OR: 1.30, 95% CI: 1.28--1.32), occupation as a farmer or rural laborer (OR: 1.16, 95% CI: 1.15--1.18), route of HIV transmission classified as injecting drug use (OR: 2.07, 95% CI: 2.02--2.12) or sexual contact and injecting drug use (OR: 1.87, 95% CI: 1.76--1.99), HIV diagnosis in a hospital (OR: 1.91, 95% CI: 1.88--1.95) or a detention center (OR: 1.75, 95% CI: 1.70--1.80), and being a migrant worker (OR: 1.55, 95% CI: 1.53--1.58). Factors associated with timely CD4 testing included being married or cohabiting with a partner (OR: 0.87, 95% CI: 0.86--0.89), being of Han ethnicity (OR: 0.76, 95% CI: 0.74--0.77), and route of HIV transmission classified as male-to-male sexual contact (OR: 0.62, 95% CI: 0.60--0.64) or commercial blood plasma donation (OR: 0.83, 95% CI: 0.81--0.87).

Baseline CD4 cell counts were also analyzed by the route of HIV infection and the year of reporting ([Table 3](#pone-0096098-t003){ref-type="table"}). There were significant differences in the distributions of CD4 cell counts by the routes of HIV infection and by the year of HIV diagnosis (heterosexual contact: χ^2^ = 119.63, p\<0.01; male-to-male sexual contact: χ^2^ = 21.07, p\<0.01; IDUs: χ^2^ = 191.85, p\<0.01; and commercial blood plasma donation: χ^2^ = 66.95, p\<0.01). Individuals infected through heterosexual contact and commercial blood plasma donation were more likely to have baseline CD4 cell counts \<200 cells/µl than individuals infected by male-to-male sexual contact, injection drug use, or sexual contact and injection drug use.

10.1371/journal.pone.0096098.t003

###### Number and percentage of newly HIV-diagnosed adults receiving baseline CD4 cell count testing within 6 months of diagnosis in China: 2006--2012, by routes of HIV transmission.
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                                                   2006   2007   2008   2009   2010   2011   2012   χ^2^                                              
  --------------------------------------- ------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------- ------ ------- ------ ---------------
  Heterosexual contact                                                                                                                                
  \<200                                    54579   1519   46.0   3043   42.0   4863   39.3   7229   39.7   9459   38.7   13277   37.7   15189   35.6  
  200--349                                 35232   712    21.5   1686   23.2   3015   24.4   4279   23.5   6031   24.7   8870    24.7   10639   24.9   χ^2^ = 119.63
  350--500                                 28918   522    15.8   1282   17.7   2298   18.6   3426   18.8   4674   19.1   7225    19.1   9491    22.3      p\<0.01
  ≥500                                     24702   552    16.7   1240   17.1   2202   17.8   3274   18.0   4261   17.4   5839    17.4   7334    17.2  
  Male-to-male sexual contact                                                                                                                         
  \<200                                    6622     70    28.7   165    24.6   371    18.3   662    18.3   1059   18.8   1822    19.6   2473    18.0  
  200--349                                 9274     65    26.6   182    27.1   575    28.4   1019   28.1   1525   27.0   2348    25.2   3560    25.9   χ^2^ = 21.07
  350--500                                 10438    54    22.1   183    27.2   568    28.1   1033   28.5   1651   29.2   2763    29.7   4186    30.4      p\<0.01
  ≥500                                     8943     55    22.5   142    21.1   511    25.2   910    25.1   1413   25.0   2383    25.6   3529    25.7  
  Injection drug use                                                                                                                                  
  \<200                                    6635    549    33.1   867    30.5   1006   27.5   1115   26.4   1051   23.3   1100    21.4    947    19.9  
  200--349                                 6158    375    22.6   660    23.2   840    23.0   991    23.5   1015   22.5   1209    23.5   1068    22.5   χ^2^ = 191.81
  350--500                                 6277    305    18.3   601    21.1   802    22.0   901    21.3   1072   23.8   1312    25.5   1284    27.0      p\<0.01
  ≥500                                     7721    431    26.0   715    25.2   1003   27.5   1213   28.8   1373   30.4   1530    29.7   1456    30.6  
  Sexual contact and injection drug use                                                                                                               
  \<200                                     566     8     40.0    19    35.8    90    24.9   140    32.9    94    20.8    126    29.2    89     24.3  
  200--349                                  482     5     25.0    10    18.9    95    26.2    86    20.2    98    21.7    92     21.3    96     26.2    χ^2^ = 0.85
  350--500                                  461     3     15.0    7     13.2    78    21.5    86    20.2   106    23.5    89     20.6    92     25.1     p = 0.36
  ≥500                                      602     4     20.0    17    32.1    99    27.3   113    26.6   154    34.1    125    28.9    90     24.5  
  Blood (plasma) donation                                                                                                                             
  \<200                                    6502    1030   66.3   1215   68.3   1129   60.6   1046   63.2   824    61.4    773    56.5    485    55.8  
  200--349                                 1867    274    17.6   290    16.3   364    19.5   281    17.0   241    17.9    247    18.1    170    19.6   χ^2^ = 66.95
  350--500                                 1152    149    9.6    143    8.0    192    10.3   178    10.8   153    11.4    198    14.5    139    16.0      p\<0.01
  ≥500                                      908    100    6.4    131    7.4    177    9.5    150    9.0    125    9.3     150    11.0    75     8.6   

The median baseline CD4 cell counts for all age groups increased slightly from 2006 to 2012 ([Figure 1](#pone-0096098-g001){ref-type="fig"}). However, the median baseline CD4 cell count for patients 45 years and older remained below 250 cells/µl over the study period. The median baseline CD4 cell counts of patients by route of transmission show none-to-little increase over the study period ([Figure 2](#pone-0096098-g002){ref-type="fig"}). Individuals infected through heterosexual contact and through commercial blood plasma donation had considerably lower median baseline CD4 cell counts than other subgroups.

![Median baseline CD4 cell counts (within 6 months of diagnosis) of newly diagnosed HIV individuals in China from 2006 to 2012, stratified by age group.\
The median baseline CD4 cell counts, stratified by age group, increased each year from 2006 to 2012. Older age groups were associated with lower median baseline CD4 cell counts.](pone.0096098.g001){#pone-0096098-g001}

![Median baseline CD4 cell counts (within 6 months of diagnosis) of newly diagnosed HIV individuals in China from 2006 to 2012, stratified by routes of infection.\
The median baseline CD4 cell counts, stratified by route of transmission, increased each year from 2006 to 2012. Subjects infected through injection drug use, male-to-male sexual contact, or sexual contact and injection drug use were consistently associated with higher median baseline CD4 cell counts compared to those infected through heterosexual contact or infected through blood (plasma) donation.](pone.0096098.g002){#pone-0096098-g002}

Discussion {#s4}
==========

The aim of our study was to identify the proportion of HIV-positive individuals in China who received baseline CD4 testing within 6 months and characteristics associated with failing to receive testing within 6 months. CD4 cell count measurements are a standard component of HIV testing algorithms to monitor disease progression. Few past studies in China [@pone.0096098-Zhang4] have evaluated access to baseline CD4 cell count testing, and this is the first study to present results on a national scale.

In the era of "Treatment as Prevention," early HIV detection, timely monitoring of disease progression, and early linkage to ART are critical steps to curbing the spread of HIV [@pone.0096098-Galvan1], [@pone.0096098-Garca1], [@pone.0096098-UNAIDS1], [@pone.0096098-Hull1]. In the United States, about 77% of HIV-diagnosed individuals are linked to care within 3--4 months, and 51% were retained in ongoing care [@pone.0096098-Centers1]. With effective interventions such as the addition of case management, the proportion of HIV-positive patients linked to ongoing care can be significantly increased compared to those who receive the standard of care [@pone.0096098-Gardner2]. As China continues to develop and expand its national AIDS programs, including the NFATP, it will be critical to have regular assessment and monitoring of the programs\' ability to link newly identified HIV-positive individuals to timely CD4 testing and treatment initiation.

To monitor the implementation of the national AIDS programs, NCAIDS developed annual quantitative targets of core program elements, including the "proportion of people known to be living with HIV whose CD4 cell counts were monitored at least once a year, to determine anti-retroviral therapy eligibility" [@pone.0096098-Liu1]. For individuals nationwide diagnosed with HIV and AIDS, this proportion rose from 45.3 and 10.1% in 2007 to 54.2 and 62.5% in 2009, respectively [@pone.0096098-Liu1]. Expanding on this previous finding, this current study shows that significant progress has also been made in increasing baseline CD4 cell count testing among HIV newly diagnosed individuals, as evidenced by the increase in CD4 cell count testing within 6 months from 20.0% in 2006 to 76.9% in 2012. The increases in CD4 monitoring of both new HIV cases and previously diagnosed cases were facilitated by structural expansions of the national AIDS programs and increases in the availability of testing materials/equipment [@pone.0096098-Zhang4], [@pone.0096098-Jiang1].

National policies recommend that the blood draw for the baseline CD4 cell count test should be completed at the first follow-up visit, which is scheduled at 14 days following the diagnosis. In our study, about 53.7% of individuals diagnosed in 2012 did not receive baseline CD4 cell count testing by the 14-day benchmark, and 23.1% did not receive CD4 cell count testing within 6 months. We identified several individual-level risk factors for failing to receive CD4 cell count testing within 6 months: age 55 years or older, male, primary school education or below, route of HIV transmission categorized as injection drug use or combined sexual contact and injection drug use, being diagnosed at a hospital or a detention center, and being a migrant worker. Some population-level factors are also likely to influence the obtainment and timing of CD4 testing. Until recent years, many county hospitals did not have the CD4 cell count testing equipment. In several regions with very low HIV prevalence, some counties and municipalities only had one CD4 detection machine for the entire area. This was likely to have delayed CD4 cell count testing for a small propotion of newly diagnosed HIV-positive individuals. Other population-level factors may include stigma and long distances between residences and clinics [@pone.0096098-Govindasamy1].

In our study, the majority of newly HIV diagnosed individuals were infected through heterosexual contact ([Table 2](#pone-0096098-t002){ref-type="table"}). This is in accordance with recent literature indicating that sexual transmission has become the dominant mode of HIV transmission in China [@pone.0096098-Dou1], [@pone.0096098-Wu2], [@pone.0096098-Wang1]. Over 60% of these individuals had baseline CD4 cell counts \<350 cells/µl over the study period ([Table 3](#pone-0096098-t003){ref-type="table"}), which is a higher proportion than those infected by male-to-male sexual contact or injection drug use. While HIV in China was historically driven by epidemics among injection drug users (IDUs), China will need to adjust to the challenges of facing an HIV epidemic that is predominantly spread by sexual contact. The group with the highest proportion (over 75%) of CD4 cell counts \<350 cells/µl were individuals infected through commercial blood plasma donation. In the mid-1990s, there were major outbreaks of HIV through unsafe commercial blood and plasma donations [@pone.0096098-Wu3], [@pone.0096098-Wu4]. The extent of the epidemic was identified through large-scale targeted screening interventions among former paid plasma donors [@pone.0096098-Wu5].

The two populations who had the highest median baseline CD4 counts were IDUs and men who have sex with men (MSM). This suggests that outreach efforts to reach these high-risk populations have produced some success in promoting early and regular HIV screening. However, MSM had the highest percentage of timely CD4 testing (78.7%) while IDUs had the lowest percentage (34.9%) when comparing subpopulations by route of transmission. Past research studies have similarly noted that MSM present with higher median CD4 levels compared to other risk groups [@pone.0096098-Buchacz1]. In our study cohort, the relative success in linking HIV-positive MSM to timely CD4 testing may also be due to a comprehensive prevention and control program in sixty-one cities from 2008 to 2009 targeted towards MSM. This program was carried out with the support of MSM community groups. This program led to policies and additional ongoing intervention programs that address HIV prevention, HIV diagnosis and CD4 cell count testing among MSM.

The barriers for IDUs to access medical care are well-documented [@pone.0096098-Celentano1]. In China, many IDUs are engaged in migrant work, have unstable lifestyles, experience stigma and discrimination from health providers, and face the fear of arrest due to the illegality of drug use in China [@pone.0096098-Zhang3]. Our study noted a slight increase of CD4 cell count levels in IDUs over the study period. In recent years, several intervention measures been taken to decrease illicit drug use and to strengthen prevention and control of HIV transmission among IDUs [@pone.0096098-Yin1], [@pone.0096098-Smith1]. Another significant strategy for engaging the HIV-positive IDU population in regular care is to expand access to methadone maintenance treatment, which has been shown to independently promote linkage to HIV care and treatment [@pone.0096098-Zhao1].

Our study found that older patients were more likely to present at late disease stages, which has been noted previously in the literature [@pone.0096098-Mugavero1]. There is currently very limited research [@pone.0096098-Liu2], [@pone.0096098-Chen1] on elderly HIV patients in China, who are not typically considered a vulnerable population for contracting HIV. According to data in CRIMS, the number of newly diagnosed individuals who were 55 years old or older has significantly increased in recent years \[unpublished data, NCAIDS, 2013\], as it has in the United States. Further studies are needed to explore issues related to the diagnosis and treatment of elderly HIV-positive patients in China.

Perhaps due to the implementation of the national AIDS programs [@pone.0096098-Liu1] the proportion of patients with advanced HIV disease (CD4 count \<200 cells/µl) has declined slightly since 2007. Of the 221,963 individuals who received timely baseline CD4 testing, the proportion of patients diagnosed late with HIV has declined slightly over the study period from 2006 to 2012. In our study cohort, 34.5% of individuals (N = 76580) had baseline CD4 counts of \<200 cells/µl and 58.8% (N = 130434) had baseline CD4 counts of \<350 cells/µl ([Table 1](#pone-0096098-t001){ref-type="table"}). Late diagnosis and late ART initiation are strongly associated with negative health outcomes, including suboptimal CD4 increases with treatment, a high rate of opportunistic infections, and increased risk of mortality [@pone.0096098-Lawn1]. Early identification of HIV and prompt monitoring are critical to improving patient outcomes and reducing disease transmission.

Our study has several limitations. First, all data is reported by local providers and may have not been uploaded to the national databases in a timely manner. While providers and CDC staff review the data for completeness and accuracy, there may be some errors in the database. Second, in most cases, the route of infection was self-reported by the individual, and some misreporting may have occurred due to stigma, particularly for the categories of male-to-male sexual contact and injection drug use. Third, while we attempted to reduce the influence of confounding variables by using multivariate analysis, it remains possible that there was confounding by unmeasured variables. Fourth, our study analysis did not assess disease progression of the newly diagnosed HIV/AIDS patients by clinical staging or viral load testing. This information is available elsewhere in CRIMS; however, a full discussion of monitoring strategies over the study period is beyond the scope of this paper. Finally, our study did not exclude individuals who died between their diagnosis and the 6-month benchmark for timely CD4 testing. These patients were included in the 8% of the study cohort who were indicated as lost to follow-up and subsequently categorized as not having received timely CD4 testing. A study that only assesses individuals who were still living 6 months after HIV diagnosis may produce higher rates of timely CD4 testing.

The risk factors identified in this study should guide future intervention strategies to increase early HIV diagnosis and CD4 cell count testing among key populations. In recent years, an increasing number of HIV cases have been identified at VCT clinics at local CDC sites, which have higher rates of linkage to baseline CD4 testing. Regional strategies that have achieved success in reducing loss to follow up and increasing linkage to care have included in-parallel Western blot confirmation testing and baseline CD4 testing (Yunnan) and compressing the timeframe from screening, confirmation, and CD4 testing (Guangxi).

This study\'s evaluation of baseline CD4 cell count testing after HIV diagnosis provides a valuable reference for further increasing testing coverage and linkage to care. Despite significant improvement, a high proportion (23.1%) of HIV-positive patients still failed to receive timely CD4 count testing in 2012, the last year of the study. To shorten the time to CD4 cell count testing and to improve access to regular testing and treatment, there should be efforts to dramatically improve referrals and integration of patient tracking between the health facilities responsible for patient follow-up, CD4 cell count testing, and ART delivery.
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